Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Xylocor Therapeutics Inc.

Headquarters: Wayne, PA, United States of America
Year Founded: 2013
Status: Private

BioCentury | Jan 11, 2025
Finance

Pre-JPM venture bonanza

Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Jul 16, 2024
Deals

Deals report: Ipsen gets second ADC; Context buys MSLN

Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Jan 19, 2022
Management Tracks

Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers

Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Mar 24, 2021
Deals

March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent

Lonnie Moulder’s cross-border biotech Zenas BioPharma launched Tuesday to develop immune-based therapies. Moulder, the co-founder and CEO of Tesaro Inc., is executive chairman and interim CEO
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

FDA will need to nail down details in its heart failure guidance to really boost investment
Items per page:
1 - 8 of 8